Merck and Co., Inc. (MRK) |
| 124.03 0.49 (0.4%) 07-13 16:02 |
| Open: | 123.58 |
| High: | 124.74 |
| Low: | 122.44 |
| Volume: | 4,954,909 |
| Market Cap: | 306,332(M) |
| PE Ratio: | 22.67 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 152.18 |
| Resistance 1: | 130.29 |
| Pivot price: | 125.12 |
| Support 1: | 118.72 |
| Support 2: | 111.57 |
| 52w High: | 130.29 |
| 52w Low: | 76.66 |
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
| EPS | 3.550 |
| Book Value | 18.580 |
| PEG Ratio | 6.22 |
| Gross Profit | 20.429 |
| Profit Margin (%) | 13.59 |
| Operating Margin (%) | 38.60 |
| Return on Assets (ttm) | 12.6 |
| Return on Equity (ttm) | 18.9 |
Mon, 13 Jul 2026
Why Merck Stock Is in the Spotlight Today - Benzinga
Fri, 10 Jul 2026
Merck (MRK) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Fri, 10 Jul 2026
Berenberg Adjusts Price Target on Merck to $127 From $125, Keeps Hold Rating - Moomoo
Thu, 09 Jul 2026
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Wed, 08 Jul 2026
Merck & Co (MRK) American Society of Clinical Oncology Annual Meeting 2025 Summary - Quartr
Wed, 08 Jul 2026
Merck & Co (MRK) Q2 2025 earnings summary - Quartr
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |